Recently, researchers have paid attention to the evaluation of the impact of SLC6A14 deletion on colon cancer in multiple preclinical model systems, comparing the effects with pharmacologic SLC6A14 blockade. This evidence concerns the gene SLC6A14 and malignant colon neoplasm.